The short answer
As a broad guide, Australian community pharmacies change hands at somewhere between three and five times normalised EBITDA, plus stock at valuation. Strong assets — medical-centre pharmacies with secure tenure, large-format stores in growing catchments, pharmacies with genuine management infrastructure that run without the owner behind the dispensary bench — trade toward and above the top of that band, and broker guidance for premium pharmacies quoted on proprietor-adjusted earnings stretches higher again. Weaker assets — heavy owner dependence, declining script volumes, a discounter across the road, a short lease with no options — sit at or below the bottom. Pharmacy valuation multiples in Australia are also quoted in several shorthand currencies: a multiple of annual gross profit (commonly somewhere around one to one-and-a-half times), dollars per annual script, or a percentage return on the total capital employed including stock. Treat all of these as cross-checks rather than methods; published transaction evidence for private pharmacies is thin, and the shorthand metrics smuggle in assumptions about margin mix and owner labour that a defensible valuation has to make explicit. One transaction convention matters before any comparison: pharmacy sales are conventionally priced plus stock at valuation, so a quoted price or multiple usually excludes several hundred thousand dollars of inventory the buyer funds on top. A multiple that looks conservative can be less so once the stock cheque is written.
The moat: location rules and ownership restrictions
Two regulatory mechanisms prop up pharmacy valuation multiples in Australia: the Pharmacy Location Rules, which restrict where a new PBS-approved pharmacy can open, and state ownership laws, which restrict pharmacy ownership to registered pharmacists. Together they make pharmacy one of the few Australian industries where the right to trade profitably in a catchment is itself a regulated, scarce thing. A pharmacy cannot dispense PBS medicines without approval under section 90 of the National Health Act 1953, and a new or relocating pharmacy generally only obtains that approval if the Australian Community Pharmacy Authority recommends it under the Pharmacy Location Rules — a determination made under section 99L of the same Act, imposing distance and catchment criteria that in practice stop a competitor opening next door. The sunset arrangements that once scheduled the rules' expiry have been removed, and the Commonwealth recommitted to the location rules framework under the Eighth Community Pharmacy Agreement. Layered on top sits state and territory ownership law: in general only registered pharmacists may own pharmacies (with limited grandfathered exceptions such as friendly societies), and jurisdictions cap the number of pharmacies in which any one pharmacist may hold an interest — Queensland's Pharmacy Business Ownership Act 2024, in full effect from 1 November 2025, retains the cap at a material interest in five pharmacy businesses and adds a licensing scheme administered by a new ownership council. For valuation, this architecture is a genuine moat. It protects the script base from new competition, makes earnings more annuity-like than almost any other retail business, and is a large part of why banks have historically financed pharmacy acquisitions at gearing levels other small businesses cannot obtain. It is why pharmacy multiples sit above general retail on comparable earnings.
The same moat caps the upside
The Pharmacy Location Rules and pharmacist-only ownership laws that prop up pharmacy values also constrain them, because they shrink the pool of buyers who are legally allowed to purchase. Market value asks what a willing but not anxious purchaser would pay — the Spencer v Commonwealth (1907) standard that underpins Australian valuation and is consistent with the market value basis in International Valuation Standard IVS 104 — and in pharmacy the pool of legally permitted purchasers is unusually narrow. Corporates, private equity and non-pharmacist consolidators cannot own the asset, so there is no strategic-buyer exit at a strategic-buyer multiple. Ownership caps mean even the most successful pharmacist-owners cannot roll up indefinitely, so the deepest-pocketed natural buyers are capacity-limited by design. The practical consequence is that pharmacies trade in a market of pharmacist purchasers whose price is bounded by what bank finance and the pharmacy's own cash flows can service — which anchors the multiple to serviceability rather than to what an open market might pay for a protected annuity. The moat is also policy, not property. The approval number, the location rules and the ownership restrictions exist at the pleasure of parliament, and reviews recommending their relaxation surface every few years. A valuation that capitalises the moat into the multiple as if it were permanent, without acknowledging that it is a regulatory setting subject to periodic challenge, overstates the certainty — and a sceptical reviewer will notice.
PBS dependence: earnings set by policy
For most community pharmacies the dispensary is the majority of turnover, and most dispensary income is determined by government — PBS reimbursement prices, dispensing fees and mark-ups are set by regulation and the Community Pharmacy Agreement, not by the pharmacy. That dependence cuts both ways, and recent history shows how fast it can move. Price disclosure has been compressing gross dollars on off-patent medicines for over a decade. Then 60-day dispensing arrived: phased in from 1 September 2023 across roughly 300 common medicines, it allows eligible patients to receive two months' supply in a single dispensing event — halving the dispensing remuneration per unit of volume on affected lines. The Eighth Community Pharmacy Agreement, which commenced 1 July 2024, returned a substantial offset: around $2.11 billion in additional dispensing remuneration across the agreement, delivered through an additional fee on eligible 60-day scripts (commencing at $4.79), a balancing fee across eligible scripts and a payment adjustment mechanism trued up six-monthly. From 1 January 2026 the general PBS co-payment fell from $31.60 to $25.00, with the concessional co-payment frozen until the end of the decade — demand-positive at the margin, but another reminder that the settings move on political timetables. The valuation consequence is specific: maintainable earnings must reflect the post-reform steady state. A trailing three-year average that straddles the 60-day tranches and the 8CPA fee changes is measuring a dispensary economics that no longer exists, and a file that capitalises it without re-basing is not supportable.
Front of shop versus dispensary
A pharmacy's gross profit splits into two economically different streams — dispensary margin, which is largely set by PBS settings, and front-of-shop margin, which is ordinary open-market retail margin — and that mix is the second structural driver of value after the moat. Dispensary gross margins are comparatively standardised by PBS settings; front-of-shop margins are retail margins — higher per dollar in many categories, but earned in open competition with discounters, supermarkets and online. The discounter segment also continues to consolidate: the merger of Chemist Warehouse and Sigma Healthcare, completed in early 2025, created the dominant force in Australian pharmacy retail, and proximity to a large-format discounter is one of the most reliable compressors of front-of-shop gross profit. Professional services are the diversification story — vaccinations, medication reviews, dose administration aids and expanding scope-of-practice programs generate fee income that is neither PBS dispensing margin nor retail margin. For the valuation file this means gross profit must be analysed by category, not read off the turnover line. A pharmacy earning eighty per cent of its gross profit from the dispensary is substantially a bet on PBS settings; a pharmacy with a strong services and front-of-shop contribution has more levers but more retail risk. Two pharmacies with identical turnover and identical EBITDA can sit at different points in the multiple range purely on mix — and the file should show why.
A worked example, with the normalisations that matter
Take a hypothetical suburban pharmacy: $4.2m turnover — $2.9m dispensary, $1.3m front of shop and services — with reported EBITDA of $520k. Three normalisations do most of the work. First, the owner is a pharmacist working a full dispensing load but drawing only $60k; restating her role at a market pharmacist-in-charge salary deducts a further $65k, because a buyer must staff those hours at market rates. Second, the premises are owned by a family trust and rent is $25k below market: deduct $25k. Third, add back a one-off legal dispute cost of $12k and the above-market portion of a family member's wages, $18k. Normalised EBITDA lands at about $460k. The next question is whether $460k is maintainable: the trailing years straddle the 60-day dispensing tranches and the 8CPA fee changes, so the file re-bases dispensary gross profit on post-reform unit economics — current fees on current script volumes — rather than averaging across the transition. Suppose the re-based figure holds at approximately $460k. At a selected multiple of 3.75x — mid-range for a stable suburban pharmacy with a long lease, steady scripts and moderate discounter exposure — enterprise value is roughly $1.7m, plus stock at valuation (say $300k funded on top). Sensitivity across 3.25x to 4.25x gives a supportable range of roughly $1.5m to $1.95m. The most supportable position within that range is a weighting decision the report has to defend on evidence: the strength of the lease, the trajectory of scripts, the catchment protection, the mix. It is not a number the vendor, the buyer or the broker nominates.
What moves a pharmacy within the range
Once earnings are normalised and re-based, the multiple question is about the durability of the moat and the quality of the earnings. These are the factors that move a specific pharmacy within the band, and each needs evidence in the file:
- ·Script volume trajectory — growing, flat or declining over the last 24 months, and the PBS versus private mix behind it
- ·Lease tenure — remaining term plus options, landlord relationship, and relocation prospects under the location rules if the site is ever lost
- ·Catchment protection — how effectively the location rules limit new approvals nearby, and any known applications
- ·Owner dependence — whether the roster runs without the owner, and the local availability and cost of employed pharmacists
- ·Gross profit mix — dispensary versus front-of-shop versus professional services contribution
- ·Discounter exposure — proximity and overlap with large-format discount competitors
- ·Regulatory posture — exposure to future PBS remuneration and dispensing-interval changes on the pharmacy's specific script profile
- ·Banner or franchise terms — fees, supply obligations and assignability on sale
- ·Stock discipline — inventory levels relative to turnover, since the buyer funds stock at valuation on top of the price
Getting to a supportable position
A formal pharmacy valuation is commissioned for partnership admissions and buyouts, related-party transfers, restructures, family succession and CGT events — the matters where a number has to hold up if it is examined, not just sound reasonable in conversation. Pharmacy is a sector where broker appraisals circulate freely and quote generous shorthand multiples; a broker's appraisal is a marketing document, prepared to support a listing, not an independent valuation under professional standards such as APES 225 that a tax position can rest on. For most pharmacy CGT and restructure matters, Prismi's Comprehensive engagement (from $3,995 + GST, 15–25 business days) is the right tier: capitalised normalised earnings as the primary methodology, a cross-check, documented add-backs and sensitivity analysis. Where the value is higher or the matter is likely to be examined — including where the position approaches the $6m maximum net asset value test for the small business CGT concessions, as many metropolitan pharmacies now do once stock and premises interests are counted — the Defensible Valuation File (from $8,995 + GST, 25–35 business days) is the appropriate level. Every report concludes at the most supportable position within the evidence-led range, is signed under an independence statement by a senior reviewer, and is prepared with the ATO's market valuation guidance in mind and documented so the position is defensible if reviewed. Prismi prepares independent valuations only — we are not a registered tax agent, and nothing here is tax, legal or financial advice; your accountant applies the valuation to the tax position. And where an engagement requires a target value rather than an evidence-led conclusion, we will say so and decline the engagement on those terms.